Literature DB >> 18059036

Does inhibition of degradation of hypoxia-inducible factor (HIF) alpha always lead to activation of HIF? Lessons learnt from the effect of proteasomal inhibition on HIF activity.

Stefan Kaluz1, Milota Kaluzová, Eric J Stanbridge.   

Abstract

At the cellular level hypoxia induces transcriptional response that is mediated by the transcription factor hypoxia-inducible factor (HIF). HIF is regulated at the level of its alpha subunit by 2-oxoglutarate (2OG)-dependent oxygenases that hydroxylate specific prolyl and asparaginyl residues of HIF-alpha, affecting its stability and activity, respectively. In the presence of O(2), the alpha subunit is degraded in a complex process with several distinct steps. In the first step, the degradation process is initiated by prolyl hydroxylases (PHDs). In the second step, the von Hippel-Lindau (VHL)/E3 ligase complex recognizes the hydroxylated HIF-alpha and mediates its polyubiquitylation by the ubiquitin-conjugating enzyme E2. In the third step, the polyubiquitylated HIF-alpha is translocated to the proteasome where it is degraded. Degradation of HIF-alpha can be inhibited at any of the three levels either by various pharmacological inhibitors or due to inactivation of genes whose products regulate the HIF system. The emerging data about inactivation of HIF under conditions of proteasomal inhibition prompted us to provide an overview contrasting the outcome of inhibition at various stages of the degradative pathway for HIF activity. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18059036     DOI: 10.1002/jcb.21644

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  11 in total

1.  Proteasome or immunoproteasome inhibitors cause apoptosis in human renal tubular epithelial cells under normoxic and hypoxic conditions.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2016-02-26       Impact factor: 2.370

2.  Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.

Authors:  Suazette Reid Mooring; Hui Jin; Narra S Devi; Adnan A Jabbar; Stefan Kaluz; Yuan Liu; Erwin G Van Meir; Binghe Wang
Journal:  J Med Chem       Date:  2011-11-23       Impact factor: 7.446

3.  Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.

Authors:  Shaoman Yin; Stefan Kaluz; Narra S Devi; Adnan A Jabbar; Rita G de Noronha; Jiyoung Mun; Zhaobin Zhang; Purushotham R Boreddy; Wei Wang; Zhibo Wang; Thomas Abbruscato; Zhengjia Chen; Jeffrey J Olson; Ruiwen Zhang; Mark M Goodman; K C Nicolaou; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2012-08-24       Impact factor: 12.531

Review 4.  Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element.

Authors:  Stefan Kaluz; Milota Kaluzová; Eric J Stanbridge
Journal:  Clin Chim Acta       Date:  2008-05-09       Impact factor: 3.786

Review 5.  The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Aamir Ahmad; Yiwei Li; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2012-05-10

6.  UBXD7 binds multiple ubiquitin ligases and implicates p97 in HIF1alpha turnover.

Authors:  Gabriela Alexandru; Johannes Graumann; Geoffrey T Smith; Natalie J Kolawa; Ruihua Fang; Raymond J Deshaies
Journal:  Cell       Date:  2008-09-05       Impact factor: 41.582

Review 7.  Functional significance of erythropoietin in renal cell carcinoma.

Authors:  Christudas Morais; David W Johnson; David A Vesey; Glenda C Gobe
Journal:  BMC Cancer       Date:  2013-01-10       Impact factor: 4.430

8.  Melittin suppresses HIF-1α/VEGF expression through inhibition of ERK and mTOR/p70S6K pathway in human cervical carcinoma cells.

Authors:  Jae-Moon Shin; Yun-Jeong Jeong; Hyun-Ji Cho; Kwan-Kyu Park; Il-Kyung Chung; In-Kyu Lee; Jong-Young Kwak; Hyeun-Wook Chang; Cheorl-Ho Kim; Sung-Kwon Moon; Wun-Jae Kim; Yung-Hyun Choi; Young-Chae Chang
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

9.  Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.

Authors:  Merryl R Lobo; Ayaka Kukino; Huong Tran; Matthias C Schabel; Charles S Springer; G Yancey Gillespie; Marjorie R Grafe; Randall L Woltjer; Martin M Pike
Journal:  PLoS One       Date:  2015-12-08       Impact factor: 3.240

Review 10.  HIF-1alpha and infectious diseases: a new frontier for the development of new therapies.

Authors:  Sânia Alves Dos Santos; Dahir Ramos de Andrade
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-12-21       Impact factor: 1.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.